Pro-senescence therapy for cancer treatment

被引：355

作者：

Nardella, Caterina ^{[1
,2
]}

Clohessy, John G. ^{[1
]}

Alimonti, Andrea ^{[1
,3
]}

Pandolfi, Pier Paolo ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Pathol & Med,Canc Genet Program, Sch Med,Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA

[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Preclin Murine Pharmacogenet Facil, Sch Med, Boston, MA 02215 USA

[3] Oncol Inst So Switzerland IOSI, CH-6500 Bellinzona, Switzerland

来源：

NATURE REVIEWS CANCER | 2011年 / 11卷 / 07期

基金：

美国国家卫生研究院;

关键词：

ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE RESPONSE; CYCLIN-DEPENDENT KINASES; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; IN-VIVO; TELOMERE DYSFUNCTION; BREAST-CANCER; P53; PATHWAY; HUMAN-CELLS;

D O I：

10.1038/nrc3057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Abundant evidence points to a crucial physiological role for cellular senescence in combating tumorigenesis. Thus, the engagement of senescence may represent a key component for therapeutic intervention in the eradication of cancer. In this Opinion article, we focus on concepts that are relevant to a pro-senescence approach to therapy and we propose potential therapeutic strategies that aim to enhance the pro-senescence response in tumours.

引用

页码：503 / 511

页数：9

共 104 条

[81] Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a)
Serrano, M
Lin, AW
McCurrach, ME
Beach, D
Lowe, SW
[J]. CELL, 1997, 88 (05) : 593 - 602
[82] Rb Regulates DNA Damage Response and Cellular Senescence through E2F-Dependent Suppression of N-Ras Isoprenylation
Shamma, Awad
Takegami, Yujiro
Miki, Takao
Kitajima, Shunsuke
Noda, Makoto
Obara, Takao
Okamoto, Takahiro
Takahashi, Chiaki
[J]. CANCER CELL, 2009, 15 (04) : 255 - 269
[83] Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis
Sidi, Roy
Pasello, Giulia
Opitz, Isabelle
Soltermann, Alex
Tutic, Michaela
Rehrauer, Hubert
Weder, Walter
Stahel, Rolf A.
Felley-Bosco, Emanuela
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 326 - 332
[84] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon, DJ
Leyland-Jones, B
Shak, S
Fuchs, H
Paton, V
Bajamonde, A
Fleming, T
Eiermann, W
Wolter, J
Pegram, M
Baselga, J
Norton, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
[85] Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
Soignet, SL
Maslak, P
Wang, ZG
Jhanwar, S
Calleja, E
Dardashti, LJ
Corso, D
DeBlasio, A
Gabrilove, J
Scheinberg, DA
Pandolfi, PP
Warrell, RP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (19) : 1341 - 1348
[86] Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner
Song, Min Sup
Carracedo, Arkaitz
Salmena, Leonardo
Song, Su Jung
Egia, Ainara
Malumbres, Marcos
Pandolfi, Pier Paolo
[J]. CELL, 2011, 144 (02) : 187 - 199
[87] Pten constrains centroacinar cell expansion and malignant transformation in the pancreas
Stanger, BZ
Stiles, B
Lauwers, GY
Bardeesy, N
Mendoza, M
Wang, Y
Greenwood, A
Cheng, KH
McLaughlin, M
Brown, D
DePinho, RA
Wu, H
Melton, DA
Dor, Y
[J]. CANCER CELL, 2005, 8 (03) : 185 - 195
[88] te Poele RH, 2002, CANCER RES, V62, P1876
[89] Pten dose dictates cancer progression in the prostate
Trotman, LC
Niki, M
Dotan, ZA
Koutcher, JA
Di Cristofano, A
Xiao, A
Khoo, AS
Roy-Burman, P
Greenberg, NM
Van Dyke, T
Cordon-Cardo, C
Pandolfi, PP
[J]. PLOS BIOLOGY, 2003, 1 (03) : 385 - 396
[90] In vivo imaging of β-galactosidase activity using far red fluorescent switch
Tung, CH
Zeng, Q
Shah, K
Kim, DE
Schellingerhout, D
Weissleder, R
[J]. CANCER RESEARCH, 2004, 64 (05) : 1579 - 1583

← 2 3 4 5 6 7 8 9 10 11 →